DK2109457T3 - Terapeutisk anvendelse af serinprotease-hæmmere af kazal-type - Google Patents

Terapeutisk anvendelse af serinprotease-hæmmere af kazal-type Download PDF

Info

Publication number
DK2109457T3
DK2109457T3 DK08707646.9T DK08707646T DK2109457T3 DK 2109457 T3 DK2109457 T3 DK 2109457T3 DK 08707646 T DK08707646 T DK 08707646T DK 2109457 T3 DK2109457 T3 DK 2109457T3
Authority
DK
Denmark
Prior art keywords
glu
leu
lys
ala
val
Prior art date
Application number
DK08707646.9T
Other languages
English (en)
Inventor
Stefan Schulte
Ulrich Kronthaler
Stefan Schmidbauer
Thomas Weimer
Kay Hofmann
Original Assignee
Csl Behring Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Csl Behring Gmbh filed Critical Csl Behring Gmbh
Application granted granted Critical
Publication of DK2109457T3 publication Critical patent/DK2109457T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • C07K14/8135—Kazal type inhibitors, e.g. pancreatic secretory inhibitor, ovomucoid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Vascular Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)

Claims (12)

1. Muterede Kazal-inhibitorer, der er afledt fra SPINK-1, hvor inhibitorerne udviser mere end 20 identiske aminosyrer med infestin-4 eller en konservativ substitution i stedet for identitet, dvs. en konservativ substitution i stedet for en identisk aminosyre, og som er egnet til forhindring af dannelse og/eller af stabilisering af tredimensionale arterielle eller venøse thromber, og hvor inhibitoren er udvalgt som tilhørende gruppen omfattende SPINK Kl, K2 og K3 (SEQ ID NO. 2, 3 og 4).
2. Muterede Kazal-inhibitorer ifølge krav 1, hvor inhibitorerne er sammenknyttet med polypeptider, der er forlængende halvlevetiden.
3. Inhibitorer ifølge krav 2, kendetegnet ved , at den halvlevetids-forlængende polypeptid er afledt fra et medlem af humant albumin-proteinfamilien, navnlig albumin, afamin, alpha-fetoprotein eller vitamin D bindende protein.
4. Inhibitorer ifølge krav 2 eller 3, kendetegnet ved , at det ved den halv-levetids-forlængende polypeptid drejer sig om humant albumin eller en variant eller et domæne eller en del deraf.
5. Inhibitorer ifølge krav 2, 3 eller 4, kendetegnet ved , at det ved den halvlevetids-forlængende polypeptid drejer sig om en immun globulin eller en del deraf.
6. Inhibitorer ifølge krav 5, kendetegnet ved, at det ved immun globulin-delen drejer sig om en igG-Fc-andel.
7. Inhibitorer ifølge krav 2, 3, 4, 5 eller 6, kendetegnet ved , at de halvlevetids-forlængende polypeptider er linket med Kasal-inhibitor-grupperingen via linkere, fortrinsvis kløvelige linkere.
8. Inhibitorer ifølge krav 7, kendetegnet ved , at linkeme er kløvelige ved koagulations-proteaser hørende til den intrinsiske koagulerings-forløbsvej.
9. Inhibitor ifølge krav 8, kendetegnet ved med FXIIa kløvelige linkere.
10. Pharmaceutisk produkt omfattende en inhibitor ifølge krav 1, 2, 3, 4, 5, 6, 7, 8 eller 9 eller omfattende en infestin eller et fragment deraf.
11. Inhibitor ifølge krav 1, 2, 3, 4, 5, 6, 7, 8 eller 9 og/eller infestin eller fragment deraf til anvendelse som et medikament.
12. Fremgangsmåde til fremstilling af en fra SPINK-1 afledt muteret Kazal-inhibitor ifølge et vilkårligt af kravene 1 til 9 ved hjælp af rekombination i eukaryotiske celler, bakterier, gær, plante- eller insekt-celler eller i transgenetiske dyr.
DK08707646.9T 2007-02-12 2008-02-11 Terapeutisk anvendelse af serinprotease-hæmmere af kazal-type DK2109457T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP07002903 2007-02-12
PCT/EP2008/001009 WO2008098720A1 (en) 2007-02-12 2008-02-11 Therapeutic application of kazal-type serine protease inhibitors

Publications (1)

Publication Number Publication Date
DK2109457T3 true DK2109457T3 (da) 2016-04-11

Family

ID=38134880

Family Applications (2)

Application Number Title Priority Date Filing Date
DK08707646.9T DK2109457T3 (da) 2007-02-12 2008-02-11 Terapeutisk anvendelse af serinprotease-hæmmere af kazal-type
DK12175363.6T DK2526962T3 (da) 2007-02-12 2008-02-11 Therapeutic application of Kazal-type serine protease inhibitors

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK12175363.6T DK2526962T3 (da) 2007-02-12 2008-02-11 Therapeutic application of Kazal-type serine protease inhibitors

Country Status (8)

Country Link
US (1) US8283319B2 (da)
EP (2) EP2109457B1 (da)
JP (1) JP2010518039A (da)
KR (1) KR101629702B1 (da)
CA (1) CA2678001C (da)
DK (2) DK2109457T3 (da)
ES (2) ES2753183T3 (da)
WO (1) WO2008098720A1 (da)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1816201A1 (en) 2006-02-06 2007-08-08 CSL Behring GmbH Modified coagulation factor VIIa with extended half-life
US20080124355A1 (en) 2006-09-22 2008-05-29 David Gordon Bermudes Live bacterial vaccines for viral infection prophylaxis or treatment
CA2673459C (en) 2006-12-22 2016-09-13 Stefan Schulte Modified coagulation factors with prolonged in vivo half-life
US8241623B1 (en) 2009-02-09 2012-08-14 David Bermudes Protease sensitivity expression system
WO2011044721A1 (zh) * 2009-10-12 2011-04-21 复旦大学 Spink6基因及其编码蛋白在制备抗肿瘤药物中的应用
US8524220B1 (en) 2010-02-09 2013-09-03 David Gordon Bermudes Protease inhibitor: protease sensitivity expression system composition and methods improving the therapeutic activity and specificity of proteins delivered by bacteria
US9597379B1 (en) 2010-02-09 2017-03-21 David Gordon Bermudes Protease inhibitor combination with therapeutic proteins including antibodies
US8771669B1 (en) 2010-02-09 2014-07-08 David Gordon Bermudes Immunization and/or treatment of parasites and infectious agents by live bacteria
EP2371857A1 (en) * 2010-04-01 2011-10-05 CSL Behring GmbH Factor XII inhibitors for treating interstitial lung disease
EP2497489A1 (en) * 2011-03-09 2012-09-12 CSL Behring GmbH Factor XII inhibitors for the treatment of silent brain ischemia and ischemia of other organs
US9352016B2 (en) 2011-03-09 2016-05-31 Csl Behring Gmbh Factor XII inhibitors for the administration with medical procedures comprising contact with artificial surfaces
IL230564B2 (en) 2011-07-22 2023-09-01 Csl Ltd Anticoagulant monoclonal antibodies anti–factor xii/fxiia, a method for their preparation, a pharmaceutical compound containing them and medical uses.
EP2548892A1 (en) 2011-07-22 2013-01-23 CSL Behring GmbH Inhibitory anti-Factor XII/XIIa monoclonal Antibodies and their uses
WO2013094240A1 (ja) * 2011-12-22 2013-06-27 国立大学法人熊本大学 モデル動物の作出方法及びモデル動物
EP2623110A1 (en) * 2012-01-31 2013-08-07 CSL Behring GmbH Factor XII inhibitors for the treatment of neurological inflammatory disorders
US10690670B2 (en) * 2013-01-20 2020-06-23 Dyax Corp. Assays for determining levels of plasma protease C1 inhibitor
US9593339B1 (en) 2013-02-14 2017-03-14 David Gordon Bermudes Bacteria carrying bacteriophage and protease inhibitors for the treatment of disorders and methods of treatment
CN105188750A (zh) 2013-03-08 2015-12-23 德国杰特贝林生物制品有限公司 治疗和预防远端缺血-再灌注损伤
RS58351B1 (sr) 2013-03-15 2019-03-29 Shire Viropharma Inc C1-inh kompozicije i postupci za prevenciju i lečenje poremećaja koji su povezani sa deficijencijom inhibitora c1 esteraze
CA2916399C (en) * 2013-06-28 2022-08-02 Marc Nolte Combination therapy using a factor xii inhibitor and a c1-inhibitor
EP3065769A4 (en) 2013-11-08 2017-05-31 Biogen MA Inc. Procoagulant fusion compound
RU2556116C2 (ru) * 2013-11-28 2015-07-10 Общество с ограниченной ответственностью "Гематологическая Корпорация" (ООО "ГемаКор") Высокоселективный ингибитор контактной активации на основе инфестина 4
JP7109160B2 (ja) 2014-06-18 2022-07-29 ツェー・エス・エル・ベーリング・ゲー・エム・ベー・ハー 神経外傷性障害において第ｘｉｉ因子インヒビターを使用する療法
KR101744959B1 (ko) 2014-12-05 2017-06-12 (주)케어젠 피부상태 개선 활성을 갖는 펩타이드 및 이의 용도
US10676723B2 (en) 2015-05-11 2020-06-09 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
US11174321B2 (en) 2016-04-06 2021-11-16 Csl Limited Method of treating atherosclerosis
US20190175683A1 (en) 2016-08-05 2019-06-13 Csl Behring Gmbh Pharmaceutical formulations of c1 esterase inhibitor
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
EP3624820A1 (en) * 2017-04-21 2020-03-25 H. Hoffnabb-La Roche Ag Use of klk5 antagonists for treatment of a disease
AU2018382222B2 (en) 2017-12-15 2025-09-04 Csl Limited Use of a FXIIa-inhibitor in the treatment of renal fibrosis and/or chronic kidney disease
US20200040103A1 (en) 2018-03-14 2020-02-06 Genentech, Inc. Anti-klk5 antibodies and methods of use
US12163956B2 (en) 2019-02-21 2024-12-10 Takeda Pharmaceutical Company Limited Lateral flow immunoassay for measuring functional C1-esterase inhibitor (C1-INH) in plasma samples
WO2020214638A1 (en) 2019-04-16 2020-10-22 Dyax Corp. Methods for quantitation of functional c1 esterase inhibitor (fc1-inh)
PH12022550646A1 (en) 2019-09-18 2023-04-03 Genentech Inc Anti-klk7 antibodies, anti-klk5 antibodies, multispecific anti-klk5/klk7 antibodies, and methods of use
WO2022109124A1 (en) 2020-11-20 2022-05-27 Csl Behring Gmbh Method for treating antibody-mediated rejection
US20240228585A1 (en) * 2021-05-03 2024-07-11 President And Fellows Of Harvard College Fc-fusion protein therapeutic for the treatment of pancreatitis

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8620926D0 (en) 1986-08-29 1986-10-08 Delta Biotechnology Ltd Yeast promoter
WO1988003171A1 (en) 1986-10-30 1988-05-05 Synergen Biologicals, Inc. Human pancreatic secretory trypsin inhibitors produced by recombinant dna methods and processes for the production of same
GB2199582A (en) * 1987-01-07 1988-07-13 Bayer Ag Analogues of pancreatic secretory trypsin inhibitor
JPH07102137B2 (ja) * 1988-07-19 1995-11-08 塩野義製薬株式会社 修飾ヒトｐｓｔｉ
DE69534265T2 (de) 1994-12-12 2006-05-04 Beth Israel Deaconess Medical Center, Inc., Boston Chimäre zytokine und ihre verwendung
DE19848785A1 (de) * 1998-10-22 2000-04-27 Max Planck Gesellschaft Gen für einen Thrombininhibitor aus Raubwanzen und Protein mit thrombinhemmender Wirkung
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
MXPA02001417A (es) * 1999-08-09 2002-08-12 Lexigen Pharm Corp Complejos multiples de citosina-anticuerpo.
EP2213743A1 (en) 2000-04-12 2010-08-04 Human Genome Sciences, Inc. Albumin fusion proteins
AU2003210806A1 (en) 2002-03-05 2003-09-22 Eli Lilly And Company Heterologous g-csf fusion proteins
CN1480466A (zh) * 2002-09-03 2004-03-10 �й������ž�����ҽѧ��ѧԺ����ҽ 一类溶栓抗凝双功能融合蛋白及应用
TWI353991B (en) * 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
PL2298347T3 (pl) 2003-05-06 2016-03-31 Bioverativ Therapeutics Inc Białka chimeryczne czynnika krzepnięcia do leczenia zaburzenia hemostazy
DK1641823T3 (da) 2003-06-12 2011-12-12 Lilly Co Eli GLP-1-analog fusionsproteiner
CA2537273A1 (en) 2003-09-05 2005-03-17 Gtc Biotherapeutics, Inc. Method for the production of fusion proteins in transgenic mammal milk
EP1696962A2 (en) * 2003-12-18 2006-09-06 Novo Nordisk A/S Novel glp-1 analogues linked to albumin-like agents
RU2370276C2 (ru) 2003-12-31 2009-10-20 Мерк Патент Гмбх Fc-ЭРИТРОПОЭТИН СЛИТЫЙ БЕЛОК С УЛУЧШЕННОЙ ФАРМАКОКИНЕТИКОЙ
US7670595B2 (en) 2004-06-28 2010-03-02 Merck Patent Gmbh Fc-interferon-beta fusion proteins
CA2591786C (en) * 2004-12-23 2013-07-16 Bernhard Nieswandt Prevention of thrombus formation and/or stabilization
BRPI0617191A2 (pt) * 2005-10-12 2011-07-19 Scripps Research Inst modificação pós-traducional de polipeptìdeos expressos em fagos

Also Published As

Publication number Publication date
WO2008098720A1 (en) 2008-08-21
EP2526962B1 (en) 2019-08-14
AU2008214916A1 (en) 2008-08-21
EP2526962A1 (en) 2012-11-28
KR20090110936A (ko) 2009-10-23
ES2753183T3 (es) 2020-04-07
CA2678001A1 (en) 2008-08-21
KR101629702B1 (ko) 2016-06-13
ES2566385T3 (es) 2016-04-12
JP2010518039A (ja) 2010-05-27
EP2109457A1 (en) 2009-10-21
US8283319B2 (en) 2012-10-09
CA2678001C (en) 2017-07-11
EP2109457B1 (en) 2016-01-06
US20100279923A1 (en) 2010-11-04
DK2526962T3 (da) 2019-10-07

Similar Documents

Publication Publication Date Title
DK2109457T3 (da) Terapeutisk anvendelse af serinprotease-hæmmere af kazal-type
AU2007214011B2 (en) Modified coagulation factor vila with extended half-life
EP2865760B1 (en) Factor viii, von willebrand factor or complexes thereof with prolonged in vivo half-life
AU2009212820B2 (en) Albumin-fused kunitz domain peptides
CA2649199C (en) Method of increasing the in vivo recovery of therapeutic polypeptides
AU2008214916B2 (en) Therapeutic application of Kazal-type serine protease inhibitors
AU2012258466A1 (en) Modified coagulation Factor VIIa with extended half-life
AU2013202563A1 (en) Method of increasing the in vivo recovery of therapeutic polypeptides
HK1151068B (en) Factor viii, von willebrand factor or complexes thereof with prolonged in vivo half-life